FDA Approves Alecensa (alectinib) Following Tumor Resection for People with Early-Stage, ALK-Positive Non-Small Cell Lung Cancer
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung [...]